Real-World Efficacy of First-Line Nivolumab Plus Ipilimumab and Its Practical Predictive Biomarkers in Advanced Renal Cell Carcinoma: First Analysis from RENOIR Study (KCSG GU22-13)
Cancer Research and Treatment · 2026
DOI: 10.4143/crt.2025.846 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, 2026. Verfasst von Jwa Hoon Kim und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Nivolumab, Ipilimumab, Carcinoma, Renal Cell, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
We investigated the real-world efficacy of first-line nivolumab plus ipilimumab (NI) and its predictive clinicopathological biomarkers in patients with advanced renal cell carcinoma (aRCC).Materials and Methods We retrospectively analyzed 466 patients with aRCC who started first-line NI between 2019 and 2023 at 21 Korean tertiary hospitals. The primary outcome was objective response rate (ORR). Secondary outcomes were duration of response (DoR), progression-free survival (PFS), overall survival (OS), and identification of practical clinicopathological biomarkers.
Results
Median age of patients was 65 years, and 77.7% were male. ORR was 44.8% including 5.2% of complete response, and median DoR was 39.8 months. Male sex and lung metastasis were predictive markers of objective response, and achieving complete response was significantly associated with a longer DoR (p=0.03). With a median follow-up duration of 23.7 months, the median PFS and OS were 11.5 and 44.2 months, respectively. Full exposure to 4 cycles of ipilimumab was significantly associated with better PFS and OS. Durable response could significantly predict better OS, whereas multiple metastatic sites (≥ 4) and poor IMDC risk were two independent predictors for inferior OS. Among the 50 patients who completed 2 years of NI treatment, continuation of nivolumab beyond 2 years has marginally improved OS (p=0.09).
Conclusion
First-line NI showed comparable and competent efficacy in Korean patients with aRCC. We suggest completing full exposure to ipilimumab and durable response as practical predictors of enriched benefits of NI in our real-world.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
- Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
- Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
- Division of Hemato-Oncology, Keimyung University Dongsan Hospital, Daegu, Korea.
- Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Zitieren
APA
Kim, J. H., Shin, S. J., Bae, W. K., Kim, S. H., Kim, J. Y., Im, H. S., Kim, I. H., Kim, I. H., Park, K., Kim, E. J., Choi, M., Lim, J. H., Kim, H., Lee, K., Kim, H. J., Jo, J., Lee, H. J., Kim, D., Sohn, B. S., …, & Park, J. H. (2026). Real-World Efficacy of First-Line Nivolumab Plus Ipilimumab and Its Practical Predictive Biomarkers in Advanced Renal Cell Carcinoma: First Analysis from RENOIR Study (KCSG GU22-13). Cancer Research and Treatment. https://doi.org/10.4143/crt.2025.846
Vancouver
Kim JH, Shin SJ, Bae WK, Kim SH, Kim JY, Im HS, et al. Real-World Efficacy of First-Line Nivolumab Plus Ipilimumab and Its Practical Predictive Biomarkers in Advanced Renal Cell Carcinoma: First Analysis from RENOIR Study (KCSG GU22-13). Cancer Research and Treatment. 2026. doi:10.4143/crt.2025.846
BibTeX
@article{Kim2026,
author = {Kim, Jwa Hoon and Shin, Sang Joon and Bae, Woo Kyun and Kim, Se Hyun and Kim, Jin Young and Im, Hyeon-Su and Kim, In-Ho and Kim, Il Hwan and Park, Kwonoh and Kim, Eo Jin and Choi, Mihong and Lim, Joo Han and Kim, Hyunho and Lee, Kyoungmin and Kim, Hyo-Jeong and Jo, Jungmin and Lee, Hyo Jin and Kim, Dalyong and Sohn, Byeong Seok and Park, Inkeun and Park, Ji Hyun},
title = {Real-World Efficacy of First-Line Nivolumab Plus Ipilimumab and Its Practical Predictive Biomarkers in Advanced Renal Cell Carcinoma: First Analysis from RENOIR Study (KCSG GU22-13)},
journal = {Cancer Research and Treatment},
year = {2026},
doi = {10.4143/crt.2025.846}
}
EUVIMED